Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SCAI Meeting In Brief

This article was originally published in The Gray Sheet

Executive Summary

Mitral valve repair: Cardiac Dimensions' Carillon mitral contour system for percutaneous mitral valve repair in patients with functional mitral regurgitation (FMR) met its safety and efficacy endpoints in a small feasibility study presented May 7 at the Society for Cardiovascular Angiography and Interventions annual scientific sessions in Las Vegas. FMR occurs in patients with enlarged hearts whose valve leaflets do not close properly, allowing blood to flow backwards from the left ventricle to the left atrium. According to six-month data from the 30-patient Carillon Mitral Annuloplasty Device European Union Study (AMADEUS), Carillon reduced FMR in patients with moderate-to-severe heart failure, with few major adverse events observed. The device is delivered through a catheter in the jugular vein, positioned around the valve and tightened to facilitate proper closing of the valve leaflets. A pivotal trial could be launched within the year, researchers announced. Carillon received a CE mark in Europe in January

You may also be interested in...



Will Positive PFO Closure Trials For Stroke Help Or Hurt Other Indications?

As pivotal trials for patent foramen ovale (PFO) closure devices to treat stroke start wrapping up, cardiologists are questioning what impact the trial results will have on studies for other indications

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel